Protagonist Therapeutics, Inc. (PTGX) Q3 2022 Earnings Results

Protagonist Therapeutics Beats on EPS, Stock Down 0.13%

The earnings report shows that Protagonist Therapeutics exceeded expectations on EPS, which is a positive sign for investors. However, the stock reaction was slightly negative, declining by 0.13%. This could indicate that investors are looking for more clarity on revenue and future guidance, which was not provided in this report.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.64	N/A	+31.91%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed a cautious optimism regarding ongoing projects. They noted the importance of continued focus on their clinical developments.

Management highlighted the progress in their clinical trials.

They emphasized their commitment to advancing their pipeline despite current challenges.

Protagonist Therapeutics Beats on EPS, Stock Down 0.13%

Key numbers

Management commentary

Protagonist Therapeutics, Inc.

More earnings this week

Protagonist Therapeutics Beats on EPS, Stock Down 0.13%

Key numbers

Management commentary